Objective:To investigate the efficacy and safety of tigecycline as a second-line therapy in the treatment of pulmonary infections in patients with hematologic diseases. Methods:When pulmonary infection can not be controlled in patients with hematologic diseases by first-line anti-infective therapy,especially existing etiological evidence or clinical suspicion of multi-drug resistant infection,we should consider tigecycline as an experiential second-line therapy in combination with other anti-infection antibiotics. The clinical data were analyzed to evaluate the efficacy and safety of this regimen. Results:A total of 50 cases of patients with hematologic diseases and pulmonary infection received this regimen. Eleven cases were cured,11 cases were in partial remission,16 cases were partial effection,and 8 cases were ineffective. The cure rate was 22% and the total effective rate was 76%. The onset time was 2-6 days (average 3.2 days). Seven cases died,and 5 cases attributed to uncontrolled infection. The most common adverse reactions in patients were vomit and diarrhea. The side effects were generally well-tolerated after symptomatic treatment. Conclusion:According to this study,the regimen of tigecycline as an experiential second-line therapy is effective and well-tolerated.